JP6117208B2 - c−kitキナーゼインヒビターとしての化合物及び組成物 - Google Patents

c−kitキナーゼインヒビターとしての化合物及び組成物 Download PDF

Info

Publication number
JP6117208B2
JP6117208B2 JP2014528513A JP2014528513A JP6117208B2 JP 6117208 B2 JP6117208 B2 JP 6117208B2 JP 2014528513 A JP2014528513 A JP 2014528513A JP 2014528513 A JP2014528513 A JP 2014528513A JP 6117208 B2 JP6117208 B2 JP 6117208B2
Authority
JP
Japan
Prior art keywords
oxadiazol
pyridine
imidazo
carboxamide
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014528513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525444A5 (https=
JP2014525444A (ja
Inventor
イエ,ヴィンス
リー,シャオリン
リュー,シャオドン
ローレン,ジョン
モルテーニ,ヴァレンチナ
ナバッカ,ジュリエット
グエン,バオ
マイケル ジェームス ペトラッシ,ハンク
マイケル ジェームス ペトラッシ,ハンク
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2014525444A publication Critical patent/JP2014525444A/ja
Publication of JP2014525444A5 publication Critical patent/JP2014525444A5/ja
Application granted granted Critical
Publication of JP6117208B2 publication Critical patent/JP6117208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014528513A 2011-09-01 2012-08-28 c−kitキナーゼインヒビターとしての化合物及び組成物 Active JP6117208B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01
US61/530,028 2011-09-01
PCT/US2012/052621 WO2013033070A1 (en) 2011-09-01 2012-08-28 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

Publications (3)

Publication Number Publication Date
JP2014525444A JP2014525444A (ja) 2014-09-29
JP2014525444A5 JP2014525444A5 (https=) 2015-10-29
JP6117208B2 true JP6117208B2 (ja) 2017-04-19

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528513A Active JP6117208B2 (ja) 2011-09-01 2012-08-28 c−kitキナーゼインヒビターとしての化合物及び組成物

Country Status (42)

Country Link
US (1) US9199981B2 (https=)
EP (1) EP2751102B1 (https=)
JP (1) JP6117208B2 (https=)
KR (1) KR101959590B1 (https=)
CN (1) CN103764653B (https=)
AP (1) AP2014007494A0 (https=)
AR (1) AR087752A1 (https=)
AU (1) AU2012300248B2 (https=)
BR (1) BR112014004504B1 (https=)
CA (1) CA2845159C (https=)
CL (1) CL2014000494A1 (https=)
CO (1) CO6900140A2 (https=)
CR (1) CR20140106A (https=)
CU (1) CU20140023A7 (https=)
CY (1) CY1121695T1 (https=)
DK (1) DK2751102T3 (https=)
EA (1) EA024293B1 (https=)
ES (1) ES2732671T3 (https=)
GT (1) GT201400036A (https=)
HR (1) HRP20191140T1 (https=)
HU (1) HUE044373T2 (https=)
IL (1) IL231226A (https=)
JO (1) JOP20120246B1 (https=)
LT (1) LT2751102T (https=)
MA (1) MA35459B1 (https=)
ME (1) ME03395B (https=)
MX (1) MX342329B (https=)
MY (1) MY167245A (https=)
PE (1) PE20141033A1 (https=)
PH (1) PH12014500351B1 (https=)
PL (1) PL2751102T3 (https=)
PT (1) PT2751102T (https=)
RS (1) RS59025B1 (https=)
SG (1) SG2014011050A (https=)
SI (1) SI2751102T1 (https=)
TN (1) TN2014000061A1 (https=)
TR (1) TR201909189T4 (https=)
TW (1) TWI543981B (https=)
UA (1) UA110841C2 (https=)
UY (1) UY34300A (https=)
WO (1) WO2013033070A1 (https=)
ZA (1) ZA201401113B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CN103797011B (zh) 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
CA2932482A1 (en) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Aryl- and hetaryl-substituted imidazo[1,2-a]pyridine-3-carboxamides and use thereof
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
UA125171C2 (uk) 2015-07-02 2022-01-26 Янссен Саєнсиз Айрленд Юсі Антибактеріальні сполуки
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
US20200308169A1 (en) 2016-06-16 2020-10-01 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
JP2019518046A (ja) 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
KR20190121315A (ko) 2017-03-01 2019-10-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 병용 요법
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
MA55976A (fr) * 2019-05-13 2022-03-23 Novartis Ag Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide
US20220340564A1 (en) 2019-09-13 2022-10-27 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
DK4122923T3 (da) * 2020-03-17 2025-12-15 Sumitomo Pharma Co Ltd Oxadiazolderivat
JP2023534963A (ja) * 2020-07-15 2023-08-15 サード ハーモニック バイオ, インコーポレイテッド 選択的c-kitキナーゼ阻害剤の結晶質形態
US20220175740A1 (en) * 2020-11-19 2022-06-09 Novartis Ag Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
US11744823B2 (en) 2020-11-19 2023-09-05 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor
MX2023010947A (es) 2021-03-16 2023-11-29 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
EP4423097A1 (en) 2021-10-28 2024-09-04 Janssen Sciences Ireland Unlimited Company Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
JP2025540958A (ja) 2022-11-30 2025-12-17 ブループリント メディシンズ コーポレイション 蕁麻疹の治療のための野生型c-kitキナーゼ阻害剤としてのN-フェニル-ピラゾロ[1,5-A]ピリジン-3-カルボキサミド誘導体
AU2023390239A1 (en) * 2022-12-07 2025-07-24 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
US20250042898A1 (en) * 2023-07-25 2025-02-06 Enanta Pharmaceuticals, Inc. Pharmaceutical Compounds And Compositions As c-Kit Kinase Inhibitors
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
TW202542157A (zh) * 2024-01-04 2025-11-01 大陸商上海翰森生物醫藥科技有限公司 多環類衍生物抑制劑、其製備方法和應用
WO2025256552A1 (zh) * 2024-06-11 2025-12-18 上海翰森生物医药科技有限公司 吡唑类衍生物抑制剂、其制备方法和应用
WO2025259929A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
CN121181581A (zh) * 2024-06-21 2025-12-23 上海美悦生物科技发展有限公司 一种稠杂环化合物、其制备方法和用途
CN121426815A (zh) * 2024-07-30 2026-01-30 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途
WO2026032333A1 (zh) * 2024-08-06 2026-02-12 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2008058037A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2011329233A1 (en) * 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
US20150051206A1 (en) * 2011-09-01 2015-02-19 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CN103797011B (zh) * 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
EA201490537A1 (ru) * 2011-09-01 2014-07-30 АйАрЭм ЭлЭлСи СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit

Also Published As

Publication number Publication date
EA201490540A1 (ru) 2014-06-30
RS59025B1 (sr) 2019-08-30
GT201400036A (es) 2015-06-02
SI2751102T1 (sl) 2019-08-30
UA110841C2 (uk) 2016-02-25
TWI543981B (zh) 2016-08-01
US20130059846A1 (en) 2013-03-07
ES2732671T3 (es) 2019-11-25
CN103764653A (zh) 2014-04-30
ZA201401113B (en) 2015-10-28
AP2014007494A0 (en) 2014-03-31
ME03395B (me) 2020-01-20
JOP20120246B1 (ar) 2022-03-14
CR20140106A (es) 2014-05-02
TN2014000061A1 (en) 2015-07-01
PH12014500351B1 (en) 2019-04-03
KR101959590B1 (ko) 2019-03-18
US9199981B2 (en) 2015-12-01
MY167245A (en) 2018-08-14
KR20140071382A (ko) 2014-06-11
PE20141033A1 (es) 2014-08-30
AR087752A1 (es) 2014-04-16
CN103764653B (zh) 2015-12-02
EP2751102A1 (en) 2014-07-09
PT2751102T (pt) 2019-07-10
TR201909189T4 (tr) 2019-07-22
BR112014004504B1 (pt) 2022-03-22
DK2751102T3 (da) 2019-07-01
PH12014500351A1 (en) 2014-04-07
CA2845159A1 (en) 2013-03-07
NZ621092A (en) 2016-06-24
CY1121695T1 (el) 2020-07-31
AU2012300248A1 (en) 2014-04-17
CU20140023A7 (es) 2014-04-24
SG2014011050A (en) 2014-08-28
PL2751102T3 (pl) 2019-09-30
LT2751102T (lt) 2019-07-10
HUE044373T2 (hu) 2019-10-28
MX2014002482A (es) 2014-11-25
AU2012300248B2 (en) 2015-08-27
CA2845159C (en) 2020-11-03
EA024293B1 (ru) 2016-09-30
UY34300A (es) 2013-04-05
WO2013033070A1 (en) 2013-03-07
IL231226A (en) 2017-03-30
MX342329B (es) 2016-09-26
IL231226A0 (en) 2014-04-30
CL2014000494A1 (es) 2014-09-05
BR112014004504A2 (pt) 2017-03-28
MA35459B1 (fr) 2014-09-01
TW201313716A (zh) 2013-04-01
CO6900140A2 (es) 2014-03-20
EP2751102B1 (en) 2019-03-27
HRP20191140T1 (hr) 2019-09-20
JP2014525444A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
JP6117208B2 (ja) c−kitキナーゼインヒビターとしての化合物及び組成物
JP6134319B2 (ja) c−kitキナーゼインヒビターとしての化合物及び組成物
JP2014525450A (ja) c−Kitキナーゼ阻害剤としての化合物および組成物
JP2014525447A (ja) c−Kitキナーゼ阻害剤としての化合物および組成物
JP2014525462A (ja) Pdgfrキナーゼ阻害剤としての化合物および組成物
HK1193820B (en) Compounds and compositions as c-kit kinase inhibitors
HK1193820A (en) Compounds and compositions as c-kit kinase inhibitors
HK1193821A (en) Compounds and compositions as c-kit kinase inhibitors
HK1193821B (en) Compounds and compositions as c-kit kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150831

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170322

R150 Certificate of patent or registration of utility model

Ref document number: 6117208

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250